G.P.S. Raghava | Bioinformatics Centre | IMTECH | CRDD | Team Members | Contact Us


  • Home
  • Facility to Community

  • Types of Antibody

  • Antibody Basics
  • Polyclonal Antibody
  • Monoclonal Antibody
  • Recombinant Antibody
  • Chimeric Antibody
  • Antibody Phage Display
  • Humanized Antibody
  • Superantibody
  • Catalytic antibody

  • Antibody : Resources

  • Antibody:Databases & Softwares
  • Antibody: Validation
  • Antibody: Suppliers
  • Antibody: Sequencing
  • Antibody: Literature

  • Techniques and Protocols

  • ELISA Radioimmunoassay
  • Antibody Microarrays

  • Important Links

  • Wiki Pages
  • Slides (PPT/PDF)

  • Chimeric Antibodies

    A chimeric antibody is a hybrid substance combining antibodies and parts of antibodies with the potential to track down and illuminate remote and microscopic tumors. It is less easily rejected by the body's immune system than the ordinary monoclonal antibody.

    What are chimeric antibodies ?

    A chimeric antibody is an antibody made by combining genetic material from a nonhuman source, like a mouse, with genetic material from a human being. Chimeric antibodies are generally around two thirds human, reducing the risk of a reaction to foreign antibodies from a non-human animal when they are used in therapeutic treatments. A closely related concept is a humanized antibody, made in a similar way but containing closer to 90% human genetic material.
    Work on the development of chimeric antibodies began in the 1980s, as scientists began exploring the possibilities of recombinant technology in genetic research. Using recombinant technology, people can cut and splice genetic material from multiple sources and fuse it together. A chimeric antibody contains antibodies developed with animal cells in culture, with sections of the genetic code replaced with human genes in order to address concerns about a potential reaction with the animal's genetic material.

    Production of chimeric antibodies

    Antibody (mouse or other) variable region will be subcloned into a proprietary vector for construction of chimeric antibody with human IgG backbone (IgG1, 2, 3, or 4). Once sequence confirmed, the expression vector will be transfected in CHO-S using Amaxa Nucleofector II. Supernatant of transfectant pools will be purified by Protein A chromatography. Two milligrams (2 mg) of recombinant antibody/Fc fusion protein (reagent grade- suitable for biochemical assays) will be delivered to customer for research purposes. Final product concentration will be analyzed by UV280, and purity will be assessed by SDS-PAGE. An optional FACS analysis is suggested to validate chimeric antibody/Fc fusion protein construct binding activity to target cell line.

    Protocol for Chimeric antibodies

    Uses of chimeric antibodies

    Monoclonal Antibody chimerization is an important and powerful tool to reduce s immunogenicity when injected into a different species. Chimerization or humanization is also a must-do step to convert a mouse monoclonal antibody into a therapeutic antibody candidate for human use. Even for in vitro applications such as Immunohistochemistry studies or ELISA assay development, switching the antibody constant regions to match the species of the host or secondary antibody could significantly reduce the background staining.